Technology area: Biotechnology & Pharmaceuticals
19 pending office actions • 14 art units • 18 examiners • 0 of 19 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Hanmi Pharm. Co., Ltd. has 19 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 17 distinct examiners and 13 distinct art units, creating a broad prosecution footprint with repeated examiner and art-unit assignments. The action count exceeds both assignment counts, so some examiners and units handle multiple matters.
YANG, TIAN is the busiest examiner, with 2 pending matters. That examiner has the largest listed individual assignment, but the portfolio remains distributed across many other examiners and units.
Counsel should use a portfolio-level system for scientific terminology, disclosure support, and claim-family consistency, while preserving matter-specific review of cited art and amendments. Art-unit grouping can help identify recurring examination patterns, but the examiner spread makes one uniform response strategy inappropriate. A dashboard organized by examiner, art unit, and pending action would support prioritization without obscuring application-specific issues.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (5%) |
| §101 + other | 1 (5%) |
| §103 only | 7 (37%) |
| §112 only | 2 (11%) |
| Double-patenting + other | 4 (21%) |
| Multi-statute (no §101) | 4 (21%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES-FOSTER, ERICA NICOLE | 2 | 49.4% | +44.0% |
| LEE, SIN J | 1 | 68.8% | +25.1% |
| SHIM, DAVID M. | 1 | 58.8% | +58.5% |
| CRAIGO, WILLIAM A | 1 | 48.9% | +38.1% |
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
| DRISCOLL, MAUREEN VARINA | 1 | 64.9% | +41.8% |
| YANG, TIAN | 1 | — | — |
| YOUTCHOM PENDIE, EMMANUEL LED | 1 | 64.3% | +41.7% |
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
| ROSSI, JULIA ANNE LORRAIN | 1 | 45.7% | +61.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17416880 | A PHARMACEUTICAL COMPOSITION COMPRISING INSULIN AND TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | SABILA, MERCY HELLEN | 22d |
| 17282661 | THERAPEUTIC USE OF GLUCAGON AND COMBINATION INCLUDING THE SAME | KONOPELSKI SNAVEL, SARA ELIZABETH | 22d |
| 18858180 | PHARMACEUTICAL COMPOSITION COMPRISING ACETYLSALICYLIC ACID AND PROTON PUMP INHIBITOR | LEE, SIN J | — |
| 18573657 | NON-NATURAL 5'-UNTRANSLATED REGION AND 3'-UNTRANSLATED REGION AND USE THEREOF | BRETZ, COREY LANE | — |
| 18554236 | COMBINATION THERAPY WITH A RAF INHIBITOR AND A PD-1 AXIS INHIBITOR | YANG, TIAN | — |
| 18036580 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF RENAL DISEASES CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | JONES-FOSTER, ERICA NICOLE | — |
| 17113571 | METHODS OF TREATING CHEMOTHERAPY OR RADIOTHERAPY INDUCED NEUTROPENIA | SCHMITT, MICHAEL J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036538 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF NEUROPATHY CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | JONES-FOSTER, ERICA NICOLE | 36d overdue |
| 18858180 | PHARMACEUTICAL COMPOSITION COMPRISING ACETYLSALICYLIC ACID AND PROTON PUMP INHIBITOR | LEE, SIN J | — |
| 18696960 | PIKFYVE KINASE INHIBITOR | SHIM, DAVID M. | — |
| 18832725 | LIQUID FORMULATION COMPRISING A FUSION PROTEIN INCLUDING a-GALACTOSIDASE A | CRAIGO, WILLIAM A | — |
| 18565628 | THERAPEUTIC USE OF COMBINATION INCLUDING TRIPLE AGONIST HAVING ACTIVITIES TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS | DRISCOLL, MAUREEN VARINA | — |
| 18036580 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF RENAL DISEASES CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | JONES-FOSTER, ERICA NICOLE | — |
| 18041151 | HYPOTENSIVE PHARMACEUTICAL COMPOSITION COMPRISING TRIPLE ACTIVATOR HAVING ACTIVITY FOR ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS | YOUTCHOM PENDIE, EMMANUEL LED | — |
| 18040869 | PHARMACEUTICAL COMPOSITION COMPRISING LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | CHANDRA, GYAN | — |
| Art Unit | Apps |
|---|---|
| 1615 | 3 |
| 1674 | 2 |
| 1656 | 2 |
| 1654 | 2 |
| 1613 | 1 |
| 1626 | 1 |
| 1635 | 1 |
| 1644 | 1 |
| 1647 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18858180 | PHARMACEUTICAL COMPOSITION COMPRISING ACETYLSALICYLIC ACID AND PROTON PUMP INHIBITOR | LEE, SIN J | 1613 | §102§103§112 | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18696960 | PIKFYVE KINASE INHIBITOR | SHIM, DAVID M. | 1626 | §112 | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18832725 | LIQUID FORMULATION COMPRISING A FUSION PROTEIN INCLUDING a-GALACTOSIDASE A | CRAIGO, WILLIAM A | 1615 | §103Other | Final Rejection | — | Pending | Jul 24, 2024 |
| 18573657 | NON-NATURAL 5'-UNTRANSLATED REGION AND 3'-UNTRANSLATED REGION AND USE THEREOF | BRETZ, COREY LANE | 1635 | §103§112DP | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18565628 | THERAPEUTIC USE OF COMBINATION INCLUDING TRIPLE AGONIST HAVING ACTIVITIES TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS | DRISCOLL, MAUREEN VARINA | 1644 | §103§112DP | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18554236 | COMBINATION THERAPY WITH A RAF INHIBITOR AND A PD-1 AXIS INHIBITOR | YANG, TIAN | 1674 | §102§103§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18036580 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF RENAL DISEASES CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | JONES-FOSTER, ERICA NICOLE | 1656 | §101 | Final Rejection | — | Pending | May 11, 2023 |
| 18036538 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF NEUROPATHY CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | JONES-FOSTER, ERICA NICOLE | 1656 | §103 | Final Rejection | 36d overdue | Pending | May 11, 2023 |
| 18041151 | HYPOTENSIVE PHARMACEUTICAL COMPOSITION COMPRISING TRIPLE ACTIVATOR HAVING ACTIVITY FOR ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS | YOUTCHOM PENDIE, EMMANUEL LED | 1647 | §112 | Non-Final OA | — | Pending | Feb 09, 2023 |
| 18040869 | PHARMACEUTICAL COMPOSITION COMPRISING LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | CHANDRA, GYAN | 1674 | §103DP | Non-Final OA | — | Pending | Feb 07, 2023 |
| 18016165 | THERAPEUTIC USE OF GLUCAGON DERIVATIVE OR CONJUGATE THEREOF FOR LIVER DISEASE | ROSSI, JULIA ANNE LORRAIN | 1615 | §103DP | Final Rejection | — | Pending | Jan 13, 2023 |
| 17927225 | LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLP-2 | PUTTLITZ, KARL J | 1646 | §103Other | Non-Final OA | — | Pending | Nov 22, 2022 |
| 17915976 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUCOSITIS INDUCED BY RADIOTHERAPY, CHEMOTHERAPY, OR COMBINATION THEREOF, COMPRISING GLP-2 DERIVATIVES OR LONG-ACTING CONJUGATE OF SAME | BRADLEY, CHRISTINA | 1654 | §103 | Final Rejection | 44d overdue | Pending | Sep 29, 2022 |
| 17915826 | ORAL COMPLEX TABLET COMPRISING SITAGLIPTIN, DAPAGLIFLOZIN, AND METFORMIN | KASSA, TIGABU | 1619 | §103 | Final Rejection | — | Pending | Sep 29, 2022 |
| 17788554 | COMPLEX FORMULATION COMPRISING SITAGLIPTIN AND DAPAGLIFLOZIN, AND PREPARATION METHOD THEREFOR | SCOTLAND, REBECCA LYNN | 1615 | §103Other | Final Rejection | — | Pending | Jun 23, 2022 |
| 17768515 | PHARMACEUTICAL COMPOSITION COMPRISING PROTON PUMP INHIBITOR AND ANTACID | SAEED, ALI S | 1616 | §103Other | Non-Final OA | — | Pending | Apr 13, 2022 |
| 17416880 | A PHARMACEUTICAL COMPOSITION COMPRISING INSULIN AND TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | SABILA, MERCY HELLEN | 1654 | §101§103§112Other | Non-Final OA | 22d | Pending | Jun 21, 2021 |
| 17282661 | THERAPEUTIC USE OF GLUCAGON AND COMBINATION INCLUDING THE SAME | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §102§103§112Other | Non-Final OA | 22d | Pending | Apr 02, 2021 |
| 17113571 | METHODS OF TREATING CHEMOTHERAPY OR RADIOTHERAPY INDUCED NEUTROPENIA | SCHMITT, MICHAEL J | 1629 | §102§103 | Final Rejection | — | Pending | Dec 07, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHanmi Pharm. Co., Ltd. has 19 pending office actions as of October 2026, spread across 14 art units and 18 examiners.
Erica Nicole Jones-Foster has the most, with 2 of Hanmi Pharm. Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
